切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2018, Vol. 07 ›› Issue (06) : 562 -566. doi: 10.3877/cma.j.issn.2095-3224.2018.06.011

所属专题: 文献

论著

MMR与PD-L1在Ⅱ期术后结直肠癌中的差异性表达
刘岩1, 李慧1, 赵丹丹1, 程颖1,()   
  1. 1. 130012 长春,吉林省肿瘤医院肿瘤转化医学实验室
  • 收稿日期:2017-03-28 出版日期:2018-12-25
  • 通信作者: 程颖
  • 基金资助:
    吉林省科技厅项目(No.20170622005JC)

Differential expression of MMR and PD-L1 protein in stage II colorectal cancer

Yan Liu1, Hui Li1, Dandan Zhao1, Ying Cheng1,()   

  1. 1. Medical Oncology Translational Research Lab, Jilin Cancer Hospital, Changchun 130012, China
  • Received:2017-03-28 Published:2018-12-25
  • Corresponding author: Ying Cheng
  • About author:
    Corresponding author: Cheng Ying, Email:
引用本文:

刘岩, 李慧, 赵丹丹, 程颖. MMR与PD-L1在Ⅱ期术后结直肠癌中的差异性表达[J/OL]. 中华结直肠疾病电子杂志, 2018, 07(06): 562-566.

Yan Liu, Hui Li, Dandan Zhao, Ying Cheng. Differential expression of MMR and PD-L1 protein in stage II colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2018, 07(06): 562-566.

目的

探讨错配修复基因(MMR)和细胞程序性死亡配体1(PD-L1)在Ⅱ期结直肠癌(CRC)组织中的一致性及差异性。

方法

选取2016年1月到2017年10月接受手术治疗的Ⅱ期CRC患者50例,免疫组化法检测术后病理组织标本中4种MMR蛋白:MutL同源蛋白1(MLH1)、Muts同源蛋白2(MSH2)、Muts同源蛋白6(MSH6)、减数分裂后分离蛋白2(PMS2)和PD-L1的表达,并分析二者的相关性。

结果

结直肠癌组织中MMR缺失(dMMR)率和PD-L1的阳性率分别为32%(16/50)和38%(19/50),dMMR和PD-L1双阳性的患者为20%(10/50);dMMR患者中PD-L1的阳性率高于错配修复功能完整患者,62.5%(10/16)vs 26.5%(9/34),差异具有统计学意义(χ2=5.995,P=0.027),PD-L1的表达与MLH1和MSH2表达缺失有关(P=0.024和0.049);PD-L1阳性患者(n=19)中dMMR与错配修复功能完整的发生率差异无统计学意义,52.6% vs 47.4%。

结论

PD-L1蛋白与dMMR存在差异性表达,在使用靶向药物治疗前,应综合考虑两种生物标志物的表达情况更精准地筛选患者。

Objective

To investigate the difference and consistency between MMR and PD-L1 in stage Ⅱ colorectal cancer (CRC).

Methods

A total of fifty patients performed operation from January 2016 to October 2017 and diagnosed as stageⅡCRC were enrolled in the study. The expression of MMR (MutL homolog 1 (MLH1)、MutS homolog 2 (MSH2)、MutS homolog 6 (MSH6)、Postmeiotic segregation increased 2 (PMS2) and PD-L1 were detected by immunohistochemistry, and the association between MMR and PD-L1 were analyzed.

Results

The rate of dMMR and of PD-L1 positive cases was 32% (16/50) and 39% (19/50) in total CRC specimens. 20% (10/50) positive PD-L1 patients had dMMR tumors. The expression of PD-L1 was higher in the dMMR group than in the pMMR group, the difference between the two groups was statistically significant [62.5% (10/16) vs 26.5% (9/34), χ2=5.995, P=0.027]. The expression of PD-L1 was associated with MLH1 and MSH2 loss (P=0.024 and 0.049); No different trend between expression rate of dMMR and proficient mismatch repair (52.6%, 10/19 vs 47.4%, 9/19) in positive PD-L1 stage Ⅱ CRC.

Conclusion

PD-L1 showed the difference expression in dMMR CRC tumor, it was implied that we need to take both dMMR and PD-L1 factors into consideration to screen suitable patients before targeting therapy.

图1 免疫组织化学检测MMR蛋白在结直肠癌组织中的表达。分别于200倍和400倍镜下拍照
图2 免疫组织化学检测PD-L1蛋白在结直肠癌组织中的表达。2A:PD-L1在结直肠癌组织中阳性表达;2B:PD-L1在结直肠癌组织中阴性表达;2C:PD-L1在肺癌组织中高表达(阳性对照);分别于200倍和400倍镜下拍照
表1 PD-L1表达与Ⅱ期结直肠癌患者临床病理特征的关系
表2 PD-L1在MMR蛋白中的表达情况
[1]
沈胤晨, 石远凯, 韩晓红. 结直肠癌靶向治疗研究进展[J]. 中华病理学杂志, 2015, 44(6): 430-433.
[2]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med, 2012, 366(26): 2443-2454.
[4]
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J]. N Engl J Med, 2012, 366(26): 2455-2465.
[5]
秦云, 梁莉萍, 郑兴征, 等. 免疫组织化学法检测结直肠癌四种DNA错配修复蛋白表达缺失对判断肿瘤微卫星状态的价值[J].中华病理学杂志, 2015, 44(10): 704-708.
[6]
Garg K, Leitao MM, Jr., Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities [J]. Am J Surg Pathol, 2009, 33(6): 925-933.
[7]
South CD, Yearsley M, Martin E, et al. Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer [J]. Genet Med, 2009, 11(11): 812-817.
[8]
石迎雪, 郑杰. 系统筛查微卫星不稳定性结直肠癌的意义和策略[J]. 中华病理学杂志, 2015, 44(1): 9-14.
[9]
李晓凤, 巴彩霞, 高辉, 等. Bcl-2和PD-L1在大肠癌组织中的表达及两者与大肠癌侵袭转移的相关性[J]. 癌症进展, 2011, 9(6): 725-729.
[10]
US Food and Drug Administration: Hematology/Oncology (Cancer) Approvals & Safety Notifications [EB/OL]. [2017-05-01].
[11]
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer [J]. N Engl J Med, 2012, 366(26): 2455-2465.
[12]
O′neil BH, Wallmark J, Lorente D, et al. Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 [C]. 2015, ECCO the European Cancer Congress.
[13]
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency [J]. N Engl J Med, 2015, 372(26): 2509-2520.
[14]
Droeser RA, Hirt C, Viehl CT, et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer [J]. Eur J Cancer, 2013, 49(9): 2233-2242.
[15]
冯稳, 吴新新, 郭永军, 等. 结直肠癌中微卫星不稳定性与PD-L1表达的关系及临床意义[J].中国肿瘤临床, 2017, 44(12): 589-593.
[16]
Siddique S, Tariq K, Rafiq S, et al. Sporadic early onset colorectal cancer in pakistan: a case control analysis of microsatellite instability [J]. Asian Pac J Cancer Prev, 2016, 17(5): 2587-2592.
[17]
Koopman M, Kortman GAM, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer [J]. Br J Cancer, 2009, 100(2): 266-273.
[18]
Weiss JM, Schumacher J, Allen GO, et al. Adjuvant chemotherapy for stageⅡ right-sided and left-sided colon cancer: analysis of SEER-medicare data [J]. Ann Surg Oncol, 2014, 21(6): 1781-1791.
[19]
Kim ST, Klempner SJ, Park SH, et al. Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy [J]. Oncotarget, 2017, 8(44): 77415-77423.
[1] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[2] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[3] 胡宁宁, 赵延荣, 王栋, 王胜亮, 郭源. FMNL3与肝细胞癌肝移植受者预后的相关性研究[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 283-288.
[4] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[5] 司钦亮, 毕世龙, 焦慧骁, 李世照, 陈哲禹, 武玉东. 精索去分化脂肪肉瘤两例并文献复习[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 585-590.
[6] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[7] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[8] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[9] 赵磊, 刘文志, 林峰, 于剑, 孙铭骏, 崔佑刚, 张旭, 衣宇鹏, 于宝胜, 冯宁. 深部热疗在改善结直肠癌术后辅助化疗副反应及生活质量中的作用研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 488-493.
[10] 黄海洋, 邝永龙, 陈嘉胜. 基层医院结直肠肿瘤经自然腔道取标本手术30 例分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 510-518.
[11] 任佳琪, 刁德昌, 何自衍, 张雪阳, 唐新, 李文娟, 李洪明, 卢新泉, 易小江. 网膜融合线导向的脾曲游离技术在左半结肠癌根治术中的应用[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 362-367.
[12] 张迪, 王春霞, 张学东, 李发馨, 庞淅文, 陈一锋, 张维胜, 王涛. 梗阻性左半结直肠癌自膨式金属支架置入后行腹腔镜手术与开腹手术的短期临床疗效比较[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 375-380.
[13] 张蔚林, 王哲学, 白峻阁, 黄忠诚, 肖志刚. 利用TCGA数据库构建基于miRNA的结直肠癌列线图预后模型[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 381-388.
[14] 张伟伟, 陈启, 翁和语, 黄亮. 随机森林模型预测T1 期结直肠癌淋巴结转移的初步研究[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 389-393.
[15] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
阅读次数
全文


摘要